Skip to content
Screener

Aurinia Pharmaceuticals AUPH Finite-Lived Intangible Assets, Accumulated Amortization

Finite-Lived Intangible Assets, Accumulated Amortization at other companies

ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$486.42M+18.8%
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$74.2M+52.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$12.76M
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue$83.2M+18.9%
Gross profit$76.7M+21.9%
Operating income$46.3M+131%
Net income$37.4M+73.9%
EPS (diluted)$0.28+75.0%

Balance sheet

See full
Cash & equivalents$179.8M+239%
Total debt$80.6M-17.7%
Total equity$614.9M+83.4%
Total assets$792.3M+57.6%

Cash flow

See full
Operating cash flow$52.6M+18.8%

Valuation

See full
Market cap$2.11B+40.2%
Enterprise value$2.01B+29.7%
P/E6.7×-18.1×
P/S6.8×+1.0×

Profitability

See full
Gross margin90.4%+0.8pp
Operating margin48.4%+28.4pp
Net margin100.8%+77.5pp

Returns & leverage

See full
Return on equity66.1%+48.8pp
Debt / equity0.1×-0.2×
Current ratio5.4×+0.2×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.

The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:16 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001600620-26-000062
Line itemGross Carrying ValueAccumulated AmortizationNet Carrying Amount
Acquired intellectual property and reacquired right$15,126$(12,732)$2,394
Patents2,419(1,435)984
Internal-use software implementation costs2,873(2,873)
Total intangible assets, net$20,418$(17,040)$3,378

Item 1. Financial Statements.

FAQ

What is Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
Aurinia Pharmaceuticals (AUPH) reported finite-lived intangible assets, accumulated amortization of $17.04M in Q2 2026.
How has Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization changed year-over-year?
Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization increased by 5.2% year-over-year, from $16.2M to $17.04M.
What is the long-term trend for Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization has grown at a 12.8% compound annual growth rate (CAGR), from $9.12M to $16.62M.
What does finite-lived intangible assets, accumulated amortization mean?
Finite-Lived Intangible Assets, Accumulated Amortization

Ask your AI about Aurinia Pharmaceuticals's finite-lived intangible assets, accumulated amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude